Analysis Of Related Factors Affecting The Efficacy And Prognosis Of Neoadjuvant Chemotherapy For Breast Cancer

Objective:Breast cancer has obvious specificity at the molecular level,and neoadjuvant chemotherapy plays an increasingly important role in its treatment.Toanalyze the response of breast cancer patients to neoadjuvant chemotherapy in our hospital,and to explore the influencing factors and effects of different curative effects on theprognosis of patients.Methods:The clinical and pathological data and follow-up data of382 breast cancer patients newly treated with neoadjuvant chemotherapy in the affiliated cancer hospital of xinjiang medical university on January 1,2011 to December 31,2015were retrospectively analyzed.The expressions of ER,PR,Her2 and Ki67 were detected by immunohistochemistry and the molecular typing was determined.To investigate the influencing factors and prognosis of neoadjuvant chemotherapy for breast cancer.Results:There were statistically significant differences between different molecular types of breast cancer and clinical efficacy evaluation(?~2=19.608,P<0.001)and pathological efficacyevaluation(?~2=60.470,P<0.001).Compared with Her2 overexpression type,triple-negative type has better histological and significant response(?~2=30.673,P<0.001).Her2 overexpression type has a better histological response than Luminal B type(?~2=25.480,P<0.001).The differences between the MRI evaluation and pathologicalevaluation(χ~2=48.116,P<0.001)or the ultrasonic evaluation and pathological evaluation(χ~2=30.570,P<0.001)were statistically significant.But the consistency between clinical and pathological efficacy evaluation was poor(Kappa≤0.40).Univariate analysis ofpathological complete remission after neoadjuvant chemotherapy was independent of the patient’s age,menstrual status,tumor diameter,tumor stage and surgical method(Р>0.05),but were significantly correlated with the expression of ER,PR,her-2,ki-67 andmolecular typing(P<0.05).Survival analysis showed that patients with pathological complete response after neoadjuvant chemotherapy had better prognosis,but thedifference between the two groups was not statistically significant(P>0.05).Conclusion:There was a statistically significant correlation between the molecular classification of breast cancer and the efficacy of neoadjuvant chemotherapy.Her2 overexpression type and triple-negative type were more sensitive to neoadjuvant chemotherapy and could achieve better efficacy.The consistency between clinical and pathological efficacyevaluation was poor.The expressions of ER,PR,her-2 and ki-67 and the molecular typing of breast cancer patients are the influencing factors of neoadjuvant chemotherapypathological complete response,and neoadjuvant chemotherapy pathological complete response has no significant influence on the long-term survival of patients.